HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Companyās Board of Directors granted two new employees options to purchase a total of 4,800 shares of the Companyās common stock at an exercise price per share of $16.18, which was the closing price on October 23, 2023, and restricted stock units to acquire a total of 2,400 shares of the Companyās common stock. The equity awards were granted pursuant to the Companyās 2020 Inducement Plan, which was approved by the Companyās Board of Directors in January 2020 pursuant to the āinducement exceptionā under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2Ī±. For more information about Arcus Biosciencesā clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
Contacts
Investor Inquiries:
Pia Banerjee
Head of Investor Relations & Strategy
(617) 459-2006
[email protected]
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
[email protected]
